VX-950

Quantity Order:

Formula: C36H53N7O6
M.Wt: 679.85
Solubility: Soluble in DMSO
Purity: 99%
Storage: -20C 2 years
CAS 402957-28-2

Telaprevir, also known as VX-950, co-developed by Vertex and Johnson & Johnson, is an experimental treatment for hepatitis C. It is a member of a class of antiviral drugs known as protease inhibitors[ 1] ; specifically, telaprevir inhibits the hepatitis C virus NS3.4A serine protease.[ 2]

In a randomized controlled trial of patients in whom standard treatment with peginterferon alfa-2a and ribavirin had failed, repeat treatment with the addition of telaprevir was more likely to have a sustained response than repeat treatment with peginterferon alfa-2a and ribavirin alone.[ 3]

Telaprevir is the first hepatitis C drug currently in development that has demonstrated activity in patients who have failed prior therapy

Recommended Products
GDC0941
GDC0449
GDC0879
Gefitinib
Abiraterone( CB-7598)
ABT-263
ABT- 737
ABT-888
AZD1152-HQPA
BEZ-235
BIBF1120
PTC-124
SGX-523
BIBW2992
Bortezomi b
CP-690550
Elvitegravir
FTY720
LBH-589
LY2140023( LY404039)
LY294002
NVP-AUY 922
NVP-TAE684
PD-0325901
PD-153035 hydrochloride
PF-04217903
Vandetanib
Vatalanib, Dihydrochloride Salt
VX-680 ( MK-0457) ( Tozasertib)
ZSTK-474
BIX02188
AZD2281
A-769662
Rivaroxaban
Resvera trol
Prasugrel
Eltrombopag
LY450139
AZ-23
VX-950( Telaprevir)
Calcitriol
Calc ifediol; monohydrate
R-406
CUDC-101
CP-724714
AG-1478 hydrochloride
AS-1413( Amonafide)
1H-Benzimidazole, 1-[ 4-chloro-6-( 4-morpholin yl) -1, 3, 5-triazin-2-yl] -2-( difluoromethyl) -
A-966492

Contact: orders@ biochem partner.com

Recommend to your friends